Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F17%3A10367303" target="_blank" >RIV/00179906:_____/17:10367303 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.radonc.2017.02.017" target="_blank" >http://dx.doi.org/10.1016/j.radonc.2017.02.017</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.radonc.2017.02.017" target="_blank" >10.1016/j.radonc.2017.02.017</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer

Popis výsledku v původním jazyce

Background: To test the hypothesis that atlas-based active bone marrow (ABM) -sparing intensity modulated radiation therapy (IMRT) yields similar dosimetric results compared to custom ABM-sparing IMRT for cervical cancer patients. Methods: We sampled 62 cervical cancer patients with pre-treatment FDG-PET/CT in training (n = 32) or test (n = 30) sets. ABM was defined as the subvolume of the pelvic bone marrow (PBM) with standardized uptake value (SUV) above the mean on the average FDG-PET image (ABM(Atlas)) vs the individual&apos;s PET (ABM(custom)). Both were deformed to the planning CI&apos;. Overlap between the two subvolumes was measured using the Dice coefficient. Three IMRT plans designed to spare PBM, ABM(Atlas), or ABM(custom) were compared for 30 test patients. Dosimetric parameters were used to evaluate plan quality. Results: ABM(Atlas) and ABM(custom) volumes were not significantly different (p = 0.90), with a mean Dice coefficient of 0.75, indicating good agreement. Compared to IMRT plans designed to spare PBM and ABM(custom), ABM(Atlas)-Sparing IMRT plans achieved excellent target coverage and normal tissue sparing, without reducing dose to ABMcustom, (mean ABM(custom) dose 29.4 Gy vs. 27.1 Gy vs. 26.9 Gy, respectively; p = 0.10); however, PTV coverage and bowel sparing were slightly reduced. Conclusions: Atlas-based ABM sparing IMRT is clinically feasible and may obviate the need for customized ABM-sparing as a strategy to reduce hematologic toxicity.

Název v anglickém jazyce

Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer

Popis výsledku anglicky

Background: To test the hypothesis that atlas-based active bone marrow (ABM) -sparing intensity modulated radiation therapy (IMRT) yields similar dosimetric results compared to custom ABM-sparing IMRT for cervical cancer patients. Methods: We sampled 62 cervical cancer patients with pre-treatment FDG-PET/CT in training (n = 32) or test (n = 30) sets. ABM was defined as the subvolume of the pelvic bone marrow (PBM) with standardized uptake value (SUV) above the mean on the average FDG-PET image (ABM(Atlas)) vs the individual&apos;s PET (ABM(custom)). Both were deformed to the planning CI&apos;. Overlap between the two subvolumes was measured using the Dice coefficient. Three IMRT plans designed to spare PBM, ABM(Atlas), or ABM(custom) were compared for 30 test patients. Dosimetric parameters were used to evaluate plan quality. Results: ABM(Atlas) and ABM(custom) volumes were not significantly different (p = 0.90), with a mean Dice coefficient of 0.75, indicating good agreement. Compared to IMRT plans designed to spare PBM and ABM(custom), ABM(Atlas)-Sparing IMRT plans achieved excellent target coverage and normal tissue sparing, without reducing dose to ABMcustom, (mean ABM(custom) dose 29.4 Gy vs. 27.1 Gy vs. 26.9 Gy, respectively; p = 0.10); however, PTV coverage and bowel sparing were slightly reduced. Conclusions: Atlas-based ABM sparing IMRT is clinically feasible and may obviate the need for customized ABM-sparing as a strategy to reduce hematologic toxicity.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Radiotherapy and Oncology

ISSN

0167-8140

e-ISSN

—

Svazek periodika

123

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

325-330

Kód UT WoS článku

000403028800025

EID výsledku v databázi Scopus

2-s2.0-85019613782